Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has locally advanced or metastatic stage IIIB/IV Non-small cell lung cancer
Patient has measurable disease
Patient has accessible tumor and consents to undergo a tumor biopsy \[Part II only\]
Patient is 18 years of age or older
Patient has a performance status of 0-2 on ECOG scale
Women of childbearing potential have a negative pregnancy test
Patients in Part I must: 1. be a female non-smoker with non-squamous histology who has had one or two prior systemic chemotherapies or 2. have documented EGFR mutation or EGFR gene amplification, regardless of demographic or clinical characteristics, who have had no more than two prior systemic chemotherapies.
Patients in Part II must have had one or two chemotherapy regimens for recurrent or metastatic disease
You may not be if
Patient has had chemotherapy within 2 weeks or biological therapy (e.g. bevacizumab) within 4 weeks
Patient has not recovered from adverse events from previous therapy within 4 weeks
Patient has received EGFR-TKI inhibitor/anti-EGFR mAb therapy
Patient has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy
Patient has untreated brain metastases
Patient has had radiotherapy to a field that affects the chest or abdomen, or thoracic surgery within 3 months prior to entering the study
Patient is taking part in another clinical study
Patient abuses drugs or alcohol
Patient is pregnant or breastfeeding
Subject is HIV positive
Patient has active hepatitis
Patient is using growth hormone or growth hormone inhibitors
Patient has poorly controlled diabetes mellitus
Clareo Health | Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
